- Report
- October 2024
- 194 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- March 2025
- 279 Pages
Global
From €5201EUR$5,450USD£4,358GBP
- Report
- March 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- January 2025
- 185 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- June 2024
- 143 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- May 2024
- 136 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- September 2023
- 190 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- December 2023
- 84 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- December 2021
- 213 Pages
Global
From €3543EUR$3,712USD£2,968GBP
The Oral Cancer Drug market is a subset of the larger Oncology Drugs market. Oral cancer drugs are used to treat cancers of the mouth, throat, and other areas of the head and neck. These drugs are typically administered orally, either as a pill or a liquid, and can be used to treat both early and advanced stages of cancer. Common oral cancer drugs include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy drugs are used to kill cancer cells, while targeted therapy drugs are designed to target specific cancer cells. Immunotherapy drugs are used to boost the body’s natural immune system to fight cancer.
Some companies in the Oral Cancer Drug market include Bristol-Myers Squibb, Merck, Pfizer, AstraZeneca, and Novartis. Show Less Read more
